Roivant Sciences Ltd. (ROIV) AI Stock Analysis
ROIV AI stock analysis summary
AI ResearchRoivant Sciences Ltd. (ROIV) is a biopharmaceutical and healthcare technology company with a market capitalization of $24.22B. Over the trailing twelve months, revenue totaled $7.5M with an operating margin of -25408.1%. The company holds $3.84B in cash and short-term investments as of June 30, 2026.
- Market cap
- $24.22B
- Revenue (TTM)
- $7.5M
- P/E
- —
- 1Y return
- 96.0% S&P 500 16.8%
- Avg. target
- $48.27 44.0% vs last close
Bull case
- Analysts project an average price target of $48.27, which indicates a 44.0% upside from the close of $33.53.
- The company retains substantial liquidity, ending June 30, 2026, with $3.84B in cash and short-term investments and net cash of $3.73B.
- Consensus forecasts anticipate next fiscal year revenue to surge 685.9% to $409.5M.
Bear case
- Annual revenue contracted by 71.6% in FY2026 to $8.3M, following a 5-year revenue CAGR of -19.1%.
- Cash generation remains negative, with free cash flow of -$758.6M and an operating margin of -15560.6% in FY2026.
- In the quarter ending June 30, 2026, quarterly revenue fell 33.5% year-over-year while quarterly earnings declined 96.1%.
What Roivant Sciences does
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to advancing medicine through research and development. Founded in 2014 and headquartered in London, United Kingdom, Roivant discovers and develops product candidates across diverse therapeutic areas. These include solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, and dermatological conditions such as psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, and acne. The company also develops treatments for autoimmune disorders including myasthenia gravis, warm autoimmune hemolytic anemia, and thyroid eye diseases, while conducting research into sarcoidosis and staph aureus bacteremia.
Growth and profitability
Revenue has trended lower over recent years, moving from $55.3M in FY2022 to $8.3M in FY2026, representing a 5-year revenue CAGR of -19.1%. Revenue fell 71.6% in FY2026, alongside an operating margin of -15560.6% and net income of -$299.8M, while R&D expense rose to $681.8M. In FY2024, net income reached $4.35B before returning to -$172.0M in FY2025. In the latest quarter ending June 30, 2026, revenue stood at $7.5M on a trailing-twelve-month basis, with quarterly revenue falling 33.5% year-over-year and quarterly earnings declining 96.1% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, Roivant Sciences Ltd. held $3.84B in cash and short-term investments against total debt of $107.2M, creating net cash of $3.73B. Total assets stood at $5.31B and shareholders' equity was $4.23B. The company maintains liquidity with a current ratio of 16.72 and a debt-to-equity ratio of 0.03. In FY2026, operating cash flow was -$750.3M and free cash flow was -$758.6M. Capital expenditures were $8.2M, and the company completed $319.5M in share buybacks.
Valuation and performance
Roivant Sciences Ltd. has an enterprise value of $22.86B and a market capitalization of $24.22B. Its price-to-book ratio is 6.3x, and its EV-to-EBITDA multiple is 0.7x, compared to an EV-to-EBITDA median of 12.0x for its US-listed Healthcare peer group. The stock closed at $33.53 on October 16, 2026, up 54.5% year-to-date and 96.0% over the past year, compared to a 16.8% 1-year return for the S&P 500 (SPY). Over five years, ROIV rose 457.0% versus 83.0% for the index.
What analysts expect
Roivant Sciences Ltd. carries 9 Strong Buy ratings, 2 Buy ratings, and 2 Hold ratings from analysts, with 0 Sell or Strong Sell ratings. The mean price target is $48.27, representing a 44.0% premium over the last close of $33.53. For the fiscal year ending March 31, 2027, consensus estimates project revenue of $52.1M and an EPS of -$1.58. The company has beaten EPS expectations in 3 of the last 4 quarters, with its next earnings date scheduled for November 9, 2026.
Key risks and what to watch
- Cash burn persists with FY2026 operating cash flow of -$750.3M and free cash flow of -$758.6M.
- High research commitments drove R&D expense to $681.8M in FY2026.
- Consensus estimates forecast an EPS loss of -$1.58 for the fiscal year ending March 31, 2027.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this ROIV AI stock analysis
This page is an AI-written research summary of Roivant Sciences Ltd. (ROIV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: ROIV income statement, ROIV balance sheet, ROIV key metrics, ROIV analyst forecast, ROIV chart. See the ROIV stock overview for the latest quote and news.
ROIV AI stock analysis FAQ
When is the next earnings release for Roivant Sciences Ltd.?
The company is scheduled to report earnings on November 9, 2026.
What is the analyst price target for ROIV?
The mean price target is $48.27, which is 44.0% above the last closing price of $33.53 on October 16, 2026.
How much cash and debt does Roivant Sciences Ltd. hold?
As of June 30, 2026, Roivant had $3.84B in cash and short-term investments and $107.2M in total debt, resulting in net cash of $3.73B.
Does Roivant Sciences Ltd. pay a dividend?
Roivant does not pay a dividend, but it allocated $319.5M toward share buybacks in FY2026.